| [ Summary ] |
The aim of chronic hepatitis B treatment is to lead hepatitis to an inactive phase, which is achieved by maintaining virus quantities below the specific level, because of the difficulty in complete exclusion of the hepatitis B virus. We considered the overseas guidelines for this aspect. Owing to the global differences regarding genotype distribution and the approval of therapeutic drugs, simplification may be difficult when creating guidelines. In each set of guidelines, the levels of HBe antigen, HBV DNA, and ALT, as well as presence of liver fibrosis are considered when choosing a patient who should receive treatment. In addition, regarding the choice of the nucleos(t)ide analogue, entecavir or tenofovir are recommended as the first‒line drugs. |